Given that sorafenib is the first-line systemic therapy in HCC at a later stage, it is imperative to investigate whether the sensitivity of sorafenib could be enhanced by YAP/TAZ inhibition depending on YAP/TAZ expression levels. The gene discussed is YAP1; the disease is hepatocellular carcinoma.